Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 2, 2012, Pages 185-195

  Gomes, Ana P ^a,b   Duarte, Filipe V ^a   Nunes, Patricia ^a   Hubbard, Basil P ^b   Teodoro, João S ^a   Varela, Ana T ^a   Jones, John G ^a   Sinclair, David A ^b   Palmeira, Carlos M ^a,c   Rolo, Anabela P ^a,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

AMPK; Berberine; Metabolic syndrome; Mitochondria; NAMPT; SIRT1

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; BERBERINE; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; BODY FAT; BODY MASS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE HOMEOSTASIS; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MALE; MITOCHONDRIAL RESPIRATION; MUSCLE MITOCHONDRION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTECTION; RAT; SKELETAL MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; BIOGENESIS; CELL LINE; DIET, HIGH-FAT; GLUCOSE; HORMONES; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MICE; MITOCHONDRIA; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MYOBLASTS; NAD; OBESITY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1;

RODENTIA;

EID: 83255163155     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.008     Document Type: Article

References (59)

1. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
2. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
3. Hegarty B.D., Furler S.M., Ye J., Cooney G., Kraegen E.W. The role of intramuscular lipid in insulin resistance. Acta Physiol. Scand. 2003, 178:373-383.
4. Muoio D.M., Newgard C.B. Obesity-related derangements in metabolic regulation. Annu. Rev. Biochem. 2006, 75:367-401.
5. Krebs M., Roden M. Nutrient-induced resistance in human skeletal muscle. Curr. Med. Chem. 2004, 11:901-908.
6. Petersen K.F., Dufour S., Savage D.B., Bilz S., Solomon G., Yonemitsu S., Cline G.W., Befroy D., Zemany L., Kahn B.B. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12587-12594.
7. Civitarese A.E., Ukropcova B., Carling S., Hulver M., DeFronzo R.A., Mandarino L., Ravussin E., Smith S.R. Role of adiponectin in human skeletal muscle biogenesis. Cell Metab. 2006, 4:75-87.
8. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 2006, 212:167-178.
9. Kelley D.E., He J., Menshikova E.V., Ritov V.B. Dysfunction of mitochondria in human skeletal mucle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
10. Mootha V.K., Lindfren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamaro P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
11. Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., Miyazaki Y., Kohane I., Costello M., Saccone R., Landaker E.J., Goldfine A.B., Mun E., DeFronzo R., Finlayson J., Kahn C.R., Mandarino L.J. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8466-8471.
12. Heilbronn L.K., Gan S.K., Turner N., Campbell L.V., Chisholm D.J. Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects. J. Clin. Endocrinol. Metab. 2007, 92:1467-1473.
13. Bonnard C., Durand A., Peyrol S., Chanseaume E., Chauvin M.A., Morio B., Vidal H., Rieusset H.J. Mitochondrial dysfunction results from oxidative stress in skeletal muscle of diet-induced insulin-resistant mice. J. Clin. Invest. 2008, 118:789-800.
14. Yokota T., Kinugawa S., Hirabayashi K., Matsushima S., Inoue N., Ohta Y., Hamaguchi S., Sobirin M.A., Ono T., Suga T., Kuroda S., Tanaka S., Terasaki F., Okita K., Tsutsui H. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1069-H1077.
15. Reznick R.M., Shulman G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 2006, 574:33-39.
16. Gerhart-Hines Z., Rodgers J.T., Bare O., Lerin C., Kin S.H., Mostoslavsky R., Alt F.W., Wu Z., Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26:1913-1923.
17. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological inights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
18. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Speigelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
19. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
20. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliot P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
21. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8:347-358.
22. Jeong H.W., Hsu K.C., Lee J.W., Ham M., Huh J.Y., Shin H.J., Kim W.S., Kin J.B.L. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E955-E964.
23. Bova S., Padrini R., Goldman W.F., Berman D.M., Cargnelli G. On the mechanism of vasodilating action of berberine: possible role of inositiol lipid signaling system. J. Pharmacol. Exp. Ther. 1992, 261:318-323.
24. Choi M.S., Yuk D.Y., Oh J.H., Jung H.Y., Han S.B., Moon D.C., Hon J.T. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer. Res. 2008, 28:3777-3784.
25. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
26. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: and additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47:1281-1288.
27. Turner N., Li J.Y., Gosby A., To S.W., Cheng Z., Miyoshi H., Taketo M.M., Cooney G.J., Kraegen E.W., James D.E., Hu L.H., Li J., Ye J.M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57:1414-1418.
28. Kim W.S., Lee Y.S., Cha S.H., Jeong H.W., Choe S.S., Lee M.R., Oh G.T., Park H.S., Lee K.U., Lane M.D., Kim J.B. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E812-E819.
29. Cheng Z., Pang T., Gu M., Gao A.H., Xie C.M., Li J.A., Nan F.J., Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta 2006, 1760:1682-1689.
30. Xia X., Yan J., Shen J., Tang K., Yin J., Zhang Y., Yang D., Liang H., Ye J., Weng J. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One 2011, 6:e16556.
31. + metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
32. Lan F., Cacicedo J.M., Riderman N., Ido Y. SIRT1 modulation of the acetylation satus, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283:27628-27635.
33. Rossetti L., Massillon D., Barzilai N., Vuguin P., Chen W., Hawkins M., Wu J., Wang J. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J. Biol. Chem. 1997, 272:27758-27763.
34. Jones J.G., Fagulha A., Barosa C., Bastos M., Barros L., Baptista C., Caldeira M.M., Carvalheiro M. Noninvasive analysis of hepatic glycogen kinetics before and after breakfast with deuterated water and acetaminophen. Diabetes 2006, 55:2294-2300.
35. Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O., Bain J., Stevens R., Dyck J.R.B., Newgard C.B., Lopaschuk G.D., Muoio D.M. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008, 7:45-56.
36. Frezza C., Cipolat S., Scorrano L. Organelle isolation: functional mitochondria from mouse liver, muscle and culture fibroblasts. Nat. Protoc. 2007, 2:287-295.
37. Rolo A.P., Oliveira P.J., Moreno A.J., Palmeira C.M. Bile acids effect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol. Sci. 2000, 57:177-185.
38. Brautigan D.L., Ferguson-Miller S., Margoliash E. Mitochondrial cytochrome c: preparation and activity of native and chemically modified cytochromes c. Methods Enzymol. 1978, 53:128-133.
39. Singer T.P. Determination of the activity of succinate, NADH, choline and glycerophosphate dehydrogenases. Biochim. Biophys. Acta 1994, 1363:100-124.
40. Varela A.T., Gomes A.P., Simões A.M., Teodoro J.S., Duarte F.V., Rolo A.P., Palmeira C.M. Indirubin-3'-oxime impairs mitochondrial oxidative phosphorylation and prevents mitochondrial permeability transition induction. Toxicol. Appl. Pharmacol. 2008, 233:179-185.
41. Rolo A.P., Palmeira C.M., Wallace K.B. Mitochondrially mediated synergistic cell killing by bile acids. Biochim. Biophys. Acta 2003, 1637:127-132.
42. Srere P.A., Brazil H., Gonen L. The citrate condensing enzyme of pigeon breast muscle and moth flight muscle. Acta Chem. Scand. 1963, 17:S129-S134.
43. Ruderman N.B., Saha A.K., Kraegen E.W. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003, 144:166-171.
44. Lowell B.B., Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 2000, 307:384-387.
45. Han Y., Wang Q., Song P., Zhu Y., Zou M.H. Redox regulation of AMP-activated protein kinase. PLoS One 2010, 5(2010):e15420.
46. Chen C., Zhang Y., Huang C. Berberine inhibits PTP1B activity and mimics insulin action. Biochem. Biophys. Res. Commun. 2010, 397:543-547.
47. Palmeira C.M., Rolo A.P., Berthiaume J., Bjork J.A., Wallace K.B. Hyperglycemia decreases mitochondrial function: the regulatory role of mitochondrial biogenesis. Toxicol. Appl. Pharmacol. 2007, 225:214-220.
48. Muoio D.M., Koves T.R. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. Appl. Physiol. Nutr. Metab. 2007, 32:874-883.
49. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Dish J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
50. de Kreutzenberg S.V., Ceolotto G., Papparella I., Bortoluzzi A., Semplicini A., Dalla Man C., Cobelli C., Fadini G.P., Avogaro A. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2011, 59:1006-1015.
51. Wang Z.Q., Lu F.E., Leng S.H., Fang X.S., Chen G., Wang Z.S., Dong L.P., Yan Z.Q. Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity. World J. Gastroenterol. 2008, 14:6004-6011.
52. Lu S.S., Yu Y.L., Zhu H.J., Liu X.D., Liu L., Liu Y.W., Wang P., Xie L., Wang G.J. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J. Endocrinol. 2009, 200:159-165.
53. Zhou J., Zhou S., Tang J., Zhang K., Guang L., Haung Y., Xu Y., Ying Y., Zhang L., Li D. Protective effect of berberine on beta cells in streptozotocin-and high carbohydrate/high-fat diet-induced diabetic rats. Euro. J. Pharmacol. 2009, 606:262-268.
54. Pereira G.C., Branco A.F., Matos J.A., Pereira S.L., Parke D., Perkins E.L., Serafim T.L., Sardão V.A., Santos M.S., Moreno A.J., Holy J., Oliveira P.J. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J. Pharmacol. Exp. Ther. 2007, 323:636-649.
55. Pereira C.V., Machado N.G., Oliveira P.J. Mechanisms of berberine (natural yello 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol. Sci. 2008, 105:408-417.
56. Scarpulla R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 2008, 88:611-638.
57. Rasbach K.A., Gupta R.K., Ruas J.L., Wu J., Naseri E., Estall J.L., Spiegelman B.M. PGC-1alpha regulates HIF2alpha-dependent switch in skeletal muscle fiber type. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21866-21871.
58. Lu D.Y., Tang C.H., Chen Y.H., Wei I.H. Berberine suppresses neuroinflammatory responses through AMPK-activated protein kinase activation in BV-2 microglia. J. Cell. Biochem. 2010, 110:697-705.
59. Cok A., Plaisier C., Salie M.J., Oram D.S., Chenge J., Louters L.L. Berberine acutely activates the glucose transport activity of GLUT1. Biochimie 2011, 93:1187-1192.